Published in Healthcare Finance, Tax and Law Weekly, February 14th, 2007
The agreement calls for Valeant to make an upfront payment to Jazz Pharmaceuticals and to make payments based on future Xyrem sales in Canada.
According to Jazz, Xyrem is the first and only product approved in Canada to treat cataplexy, which is a sudden loss of muscle tone associated with narcolepsy. Valeant expects to launch and distribute Xyrem in Canada in mid-2007 through its neurology sales force.
"We are excited to be partnering with Valeant, which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.